Trial · NCT02170298
Lisdexamfetamine's Effect In ADHD in the Brain and Cognition
NCT02170298, Phase 4, Terminated, University of California, Davis; results first posted 2019-12-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Lisdexamfetamine's Effect In ADHD in the Brain and Cognition. Trials, record NCT02170298. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02170298
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Lisdexamfetamine's Effect In ADHD in the Brain and Cognition
- NCT number
- NCT02170298
- Status
- Terminated
- Phases
- Phase 4
- Enrollment
- 6 participants, actual
- Lead sponsor
- University of California, Davis
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Lisdexamfetamine
- First posted
- 2014-06-23
- Last updated
- 2019-12-26
- Results first posted
- 2019-12-26
- Limitations and caveats
Data were not analyzed due to early study termination. Unable to recruit a sufficient number of subjects. Data on this measure is highly variable and low subject numbers will not produce reliable or valid data.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Working Memory | Baseline, 9 weeks | Working memory performance, as measured by the percent of items correct on the Span Working Memory Task. |
| Primary | Delay Discounting | Baseline, 9 weeks | Level of self-control, as demonstrated on the Delay Discounting Task. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Working Memory | Baseline, 9 weeks | Data were not analyzed due to early study termination. Unable to recruit a sufficient number of subjects. Data on this measure is highly variable and low subject numbers will not produce reliable or valid data. | ||
| PRIMARY | Delay Discounting | Baseline, 9 weeks | Data were not analyzed due to early study termination. Unable to recruit a sufficient number of subjects. Data on this measure is highly variable and low subject numbers will not produce reliable or valid data. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 1 | |
| Overall Study | STARTED | Lisdexamfetamine | 5 | |
| Overall Study | COMPLETED | Placebo | 0 | |
| Overall Study | COMPLETED | Lisdexamfetamine | 4 | |
| Overall Study | NOT COMPLETED | Placebo | 1 | |
| Overall Study | NOT COMPLETED | Lisdexamfetamine | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | 0 | 1 |
| Total, all-cause mortality | Lisdexamfetamine | 0 | 4 |
| Total, other adverse events | Placebo | 0 | 1 |
| Total, other adverse events | Lisdexamfetamine | 0 | 4 |
| Total, serious adverse events | Placebo | 0 | 1 |
| Total, serious adverse events | Lisdexamfetamine | 0 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Lisdexamfetamine vs Placebo: deaths from any cause | Trial comparisons |
| Lisdexamfetamine vs Placebo: serious adverse events | Trial comparisons |
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Delay Discounting | Primary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02170298
GET https://conductscience.org/api/trials/v1/NCT02170298/registered